Chinese expert consensus on big data and real world study in cancer research (2022 edition)

Abstract

Cancer is a public health and social problem to which great attention should be attached. Not only are there a large number of cancer patients in China, but great differences also exist in etiology, epidemiology, disease spectrum, and treatment between China and western countries. Therefore, tumor-related data in China has its own characteristics. Full reference to the data of western countries cannot accurately reflect the real situation of cancer prevention and treatment in China. If we can integrate, process and analyze Chinese data, and find rules in specific etiology, incidence, drug sensitivity and prognosis, it will play an important role in the formulation of health policy, medical research and disease prevention. The Society of Cancer Big Data and Real World Study of China Anti-Cancer Association organized multidisciplinary experts, combined with domestic and foreign literature and clinical practice, after repeated discussion and revision, finished this consensus including background, analysis and management, direction planning and operation flow, basic design, quality control standards, evidence level classification, data security and privacy standards of big data and real world study. The aim is to take full advantages of Chinese cancer big data to carry out high-quality real world study, and better promote the prevention and treatment of cancer in China.